stockrowGeneDx Holdings Corp.
WGS Healthcare Diagnostics & Research
GeneDx Holdings Corp.’s revenue for fiscal 2025 (year ended December 2025) was $427.5 million, up 40.0% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- −257.9%
- Free cash flow
- −585.6%
- Total debt
- +87.4%
Quarter to June 2026, against a year earlier
Follow WGS
Alert me
GeneDx Holdings Corp. (WGS) EBITDA
GeneDx Holdings Corp.'s EBITDA for fiscal 2025 was $12.1M, compared with −$1.3M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$65.5M. Over the past ten years it has ranged from −$608.3M (fiscal 2022) to $12.1M (fiscal 2025) — the current reading is the highest in ten years. EBITDA has risen for 3 consecutive fiscal years. GeneDx Holdings Corp. ranks 43rd of 49 Diagnostics & Research companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $12.1M | — |
| FY2024 | −$1.3M | — |
| FY2023 | −$146.9M | — |
| FY2022 | −$608.3M | — |
| FY2021 | −$424.3M | — |
| FY2020 | −$230.3M | — |
| FY2019 | −$24.0M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$10.7M | — |
| Mar 2026 | −$50.7M | — |
| Dec 2025 | −$7.4M | — |
| Sep 2025 | $3.2M | (78.73%) |
| 20 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| CDNA CareDx, Inc. compare | $141.4M |
| VCYT Veracyte, Inc. compare | $123.9M |
| NEO NeoGenomics, Inc. compare | $17.5M |
| FRNM Freenome, Inc compare | −$4.3M |
| CSTL Castle Biosciences, Inc. compare | −$14.0M |
| ADPT Adaptive Biotechnologies Corporation compare | −$22.4M |
| OPK OPKO Health, Inc. compare | −$37.5M |
| WGS GeneDx Holdings Corp. | −$65.5M |
| PSNL Personalis, Inc. compare | −$108.6M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on WGS
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement